Elekta and Brainlab improve interoperability and treatment capabilities in stereotactic neurosurgery treatments

MADRID, September 29, 2016 – Elekta (EKTA-B.ST) and Brainlab announced today at
the European Society of Stereotactic and Functional Neurosurgery (ESSFN) meeting
in Madrid that they have entered into a technical exchange agreement regarding
the new software from Brainlab, Elements Stereotaxy* and Elekta’s new precise
delivery system, Leksell® Vantage™ Stereotactic System**.
To ensure a continuous evolution of interoperability and safety, Elekta and
Brainlab have entered into a forward-looking technical exchange agreement that
has the potential for more patients to benefit from powerful planning
capabilities and accurate, safe treatments using Elekta and Brainlab equipment
for stereotactic neurosurgical procedures.

This collaboration is designed to enable even smoother workflows and
interoperability in stereotactic neurosurgical procedures when planning,
accurately positioning devices in the brain, and verifying treatment using
Elements and Leksell Vantage.

Based on Leksell Stereotactic System®, the gold standard within stereotactic
neurosurgery, Leksell Vantage Stereotactic System, is the latest development
from Elekta in the field of stereotactic neurosurgery. It now has a nonmetallic
head frame for neuroimaging without compromise, enhanced patient comfort, and a
new innovative arc design.

Elements Stereotaxy, in combination with Elements Automatic Segmentation,
FiberTracking and post-operative Lead Localization**, are the latest additions
to Brainlab’s product portfolio and together extend the advanced capabilities
for planning as well as intra- and postoperative verification of the lead
placement for stereotactic functional neurosurgery.

Visit our booths at ESSFN to find out more about the new products.

*This product is not available for sale and will not be available until all
applicable approvals have been acquired.
**Leksell® Vantage™ Stereotactic System is not yet CE marked or 510(k) cleared
and is not available for sale or distribution.

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on September 29, 2016.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,600 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

About Brainlab
Brainlab, headquartered in Munich, develops, manufactures and markets software
-driven medical technology, enabling access to advanced, less invasive patient
treatments.

Core products center on information-guided surgery, radiosurgery, precision
radiation therapy, digital operating room integration, and information and
knowledge exchange. Brainlab technology powers treatments in radiosurgery and
radiotherapy as well as numerous surgical fields including neurosurgery,
orthopedic, ENT, CMF, spine and trauma.

Privately held since its formation in Munich, Germany in 1989, Brainlab has more
than 11,000 systems installed in about 100 countries. Brainlab employs 1,350
people in 19 offices worldwide, including 385 Research & Development engineers,
who form a crucial part of the product development team.